DAYI Therapeutics focuses on developing antisense oligonucleotide (ASO) therapeutics for severe, single-gene (monogenic) disorders that affect the nervous system and other organs. Single-gene diseases caused by genetic mutations, for which most have no effective treatment, collectively affect 4% of the world's population, representing an over $500 billion market. DAYI aims to utilize ASOs to target the root of these diseases by precisely normalizing the expression of the disease-causing gene, leveraging the established delivery, safety, and efficacy of ASO therapeutics, as well as accelerating clinical deployment.